X-ray Brachytherapy Sustains Organ Preservation in Early Rectal Cancer
The OPERA trial's 5-year findings support contact X-ray brachytherapy (CXB) boost for organ preservation in early rectal adenocarcinoma, with higher rates in tumors <3 cm. Group B (CXB boost) showed better organ preservation and clinical response rates vs. Group A (EBRT boost). No significant OS differences, but higher DSS in Group B. Tumor size <3 cm significantly correlated with better organ preservation.
Related Clinical Trials
Highlighted Terms
Related News
The OPERA trial's 5-year findings support contact X-ray brachytherapy (CXB) boost for organ preservation in early rectal adenocarcinoma, with higher rates in tumors <3 cm. Group B (CXB boost) showed better organ preservation and clinical response rates vs. Group A (EBRT boost). No significant OS differences, but higher DSS in Group B. Tumor size <3 cm significantly correlated with better organ preservation.